Global Intravenous (IV) Iron Drugs Market: Industry Analysis & Outlook (2017-2021)

1
Industry Research by Koncept Analytics
Global Intravenous (IV) Iron Drugs Market
Industry Analysis Outlook ---------------------
-------------------- (2017-2021)
May 2017
2
Executive Summary
Iron is among the vital minerals present in the
human body. It is one of the components of
hemoglobin, the substance present in red blood
cells that carries oxygen throughout the body
through blood, and oxygen is further utilized by
the cells to produce energy required to perform
all the required functions. Therefore, decline in
the bodys supply of iron can lead to severe
problems. The balance of iron in the body
primarily is a combined result of three dynamics-
intake, losses and metabolic demand. Intravenous
(I.V.) treatment, in a broad sense, covers all
the types of medications delivered intravenously,
i.e. directly into the vein, through intravenous
(I.V.) drip. Compared to the other routes of
infusing medications, the intravenous route is
the fastest way to deliver fluids and medications
throughout the body. Also, this method ensures
100 bioavailability, which means that the
chemicals delivered are fully absorbed by the
body. The report Global I.V. Iron Drugs Market
provides a comprehensive study of iron product
market and I.V. iron market globally. It also
provides detailed information for key regional
markets of I.V iron industry. The major trends,
growth drivers as well as issues being faced by
the industry are being presented in this report.
The major players in the industry, Galenica
Group, AMAG Pharmaceuticals and Allergan are
being profiled. All these companies have been
profiled in the present report highlighting their
key financials and business strategies for
growth. The key factors driving the growth of
I.V. iron drugs market are growing ageing
population, growing urbanization, increase in
number of dialysis cases, rising healthcare
expenditure and increasing life expectancy rate.
Some of the noteworthy trends and developments of
this industry are paradigm shift from oral iron
drugs to intravenous iron drugs and introduction
of first generation drugs InFeD and Dexeferrum.
However, the expansion of the market is hindered
by potential risks of I.V. iron.
3
Rising incidence of chronic kidney disease (CKD),
iron deficiency to drive the market
Global I.V. Iron Drugs Market by Value (2010-2016)

• The global I.V. iron market was valued at US...
  million in 2016, up by , as compared to US...
  million in 2015.
• As of 2016, Ferinject remained the gold standard
  product in dialysis patients with of the
  global I.V. iron market share followed by Venofer
  and ISS with and share respectively.
• The ferric carboxymaltose segment accounted for
  the majority market share of during 2016. It
  was followed by sucrose and dextran with share of
  and respectively.

Global I.V. Iron Drugs Market Share by Product
Category (2016)
Global I.V. Iron Drugs Market Share by Segments
(2016)
4
The market growth was primarily driven by Venofer
and Ferinject.
The US I.V. Iron Drug Market by Value (2010-2016)

• The US I.V. iron drug market increased to US...
  million in 2016 from US... million in 2015,
  showing an increase of .
• The size of the total 2016 US non-dialysis IV
  iron replacement therapy market was
  approximately million grams.
• European I.V. iron drug market was valued at
  US... million in 2016, as compared to US...
  million in 2015, representing a growth of .

The US Non-dialysis I.V. Iron Drug Market by
Volume (2010-2016)
European I.V. Iron Drug Market by Value
(2010-2016)
5
Disclaimer
Contact Us
This is a licensed product of Koncept Analytics.
You cannot reproduce, publish, distribute,
publicly display, sell or create other works from
this report or use them in any way for commercial
purpose without our prior permission. Further,
you cannot copy this material, by any means
(including electronic copies), for distribution
to others unless you have purchased the corporate
license of this report. We believe the sources
are reliable, but Koncept Analytics does not
warranty the accuracy or completeness of the
data. The data presented in the report is updated
at the publication date but is subject to change
at subsequent releases. All possible efforts have
been made to ensure accuracy of data. However,
investors should not completely rely on the
information given in this report and must make
decisions based on their own investment strategy,
risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T
91-120-4130959 M 91-9811715635
vikas_at_konceptanalytics.com
www.konceptanalytics.com